In the news:Mirati Therapeutics
Add to library
ShareKey facts
- city: San Diego
- state: CA
- country: United States
- sector: Health Care
- foundation year: 2013
- industry: Biotechnology
- CEO: David D. Meek
In classification: organization
Summary
The company Mirati Therapeutics was founded in 2013 in the city of San Diego, the United States. The company is part of the Health Care sector, specifically in the Biotechnology industry.
Business
Mirati Therapeutics is one of the companies in United States, one of the companies in Biotechnology and one of the companies in Health Care. Mirati Therapeutics is one of the 3,466,499 companies in our database.
- Assets: 1.6B $
- Debt: 45.8M $
- Employees: 413 people
- Free cash flow: -222008000 $
- Market cap: 4.5B $
- Profits: -581784000 $
- Revenues: 72.8M $
Stocks from Mirati Therapeutics
Explore more on business
Talking Points:
- Mirati Therapeutics, Inc. | Relentless Focus on Innovation | Targeted Oncology
- At Mirati, we are relentlessly focused on developing best-in-class targeted therapies to meaningfully impact the lives of patients with cancer.
- Our mission is to discover, design & deliver breakthrough therapies to transform the lives of patients with cancer and their loved ones. https://t.co/nXoCkyY6VT
- 201-500 employees Headquarters San Diego, California Type Public Company Founded 2013 Locations Primary 3545 Cray Ct San Diego, California 92121, US Get directions Employees at Mirati Therapeutics...
- Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; and Sitravatinib, an investigational spectrum-selective kinase inhibitor that is in Phase 3 clinical trial for the treatment of NSCL cancer, as well as a KRAS G12D inhibitor program, which is in preclinical development. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.
Learn more about talking points